Intelligent Bio Solutions Inc. reported financial results for the fiscal second quarter ended December 31, 2025, with record revenue growth of 48% year-over-year to $896,774, driven by a 104% surge in reader sales. The company also announced a $10.0 million private placement, a new manufacturing partnership, and progress on its FDA 510(k) submission for U.S. market entry.
Key takeaways
Total revenue for Q2 fiscal 2026 was $896,774, a 48% year-over-year increase.
Reader sales grew 104% year-over-year to $246,519, while cartridge sales grew 33% to $516,754.
For the six months ended December 31, 2025, total revenue was $2.01 million, a 36% year-over-year increase.
Gross profit margin for the first half of fiscal 2026 was 49%, up 10% from the same period in 2025.
The company closed a $10.0 million private placement on January 2, 2026, with net proceeds of $9.40 million.
Current assets as of December 31, 2025, were $12.17 million, including $9.40 million receivable from the private placement.